89bio Statistics
Total Valuation
89bio has a market cap or net worth of $1.50 billion. The enterprise value is $898.06 million.
Important Dates
The next estimated earnings date is Monday, August 4, 2025, after market close.
Earnings Date | Aug 4, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
89bio has 145.98 million shares outstanding. The number of shares has increased by 43.38% in one year.
Current Share Class | 145.98M |
Shares Outstanding | 145.98M |
Shares Change (YoY) | +43.38% |
Shares Change (QoQ) | +26.22% |
Owned by Insiders (%) | 0.56% |
Owned by Institutions (%) | 76.34% |
Float | 101.62M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 2.40 |
P/TBV Ratio | 2.48 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.03, with a Debt / Equity ratio of 0.06.
Current Ratio | 18.03 |
Quick Ratio | 16.86 |
Debt / Equity | 0.06 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -70.83 |
Financial Efficiency
Return on equity (ROE) is -69.30% and return on invested capital (ROIC) is -42.69%.
Return on Equity (ROE) | -69.30% |
Return on Assets (ROA) | -39.93% |
Return on Invested Capital (ROIC) | -42.69% |
Return on Capital Employed (ROCE) | -62.32% |
Revenue Per Employee | n/a |
Profits Per Employee | -$4.16M |
Employee Count | 93 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, 89bio has paid $732,000 in taxes.
Income Tax | 732,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.01% in the last 52 weeks. The beta is 1.53, so 89bio's price volatility has been higher than the market average.
Beta (5Y) | 1.53 |
52-Week Price Change | +27.01% |
50-Day Moving Average | 7.75 |
200-Day Moving Average | 8.29 |
Relative Strength Index (RSI) | 67.79 |
Average Volume (20 Days) | 2,158,974 |
Short Selling Information
The latest short interest is 15.48 million, so 10.60% of the outstanding shares have been sold short.
Short Interest | 15.48M |
Short Previous Month | 17.31M |
Short % of Shares Out | 10.60% |
Short % of Float | 15.23% |
Short Ratio (days to cover) | 10.23 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -403.29M |
Pretax Income | -170.51M |
Net Income | -386.67M |
EBITDA | -403.25M |
EBIT | -403.29M |
Earnings Per Share (EPS) | -$3.30 |
Full Income Statement Balance Sheet
The company has $638.78 million in cash and $37.58 million in debt, giving a net cash position of $601.20 million or $4.12 per share.
Cash & Cash Equivalents | 638.78M |
Total Debt | 37.58M |
Net Cash | 601.20M |
Net Cash Per Share | $4.12 |
Equity (Book Value) | 605.46M |
Book Value Per Share | 4.15 |
Working Capital | 645.06M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$399.84 million and capital expenditures -$87,000, giving a free cash flow of -$399.93 million.
Operating Cash Flow | -399.84M |
Capital Expenditures | -87,000 |
Free Cash Flow | -399.93M |
FCF Per Share | -$2.74 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
89bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -43.38% |
Shareholder Yield | -43.38% |
Earnings Yield | -25.79% |
FCF Yield | -26.68% |
Dividend Details Analyst Forecast
The average price target for 89bio is $26.43, which is 157.85% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $26.43 |
Price Target Difference | 157.85% |
Analyst Consensus | Strong Buy |
Analyst Count | 8 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |